GlassScriptPhysician profile
Daniel Burton Reese
NPI 1770562050
$1,368.77
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $29.76 · 2021: $101 · 2022: $146 · 2023: $206 · 2024: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $428.94 | 2019-2020 | |
| Abbott Laboratories | $171.23 | 2019-2024 | Amplatzer Amulet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.29 | 2021-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.10 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $92.38 | 2019-2024 | Xarelto |
| Medtronic, INC. | $90.78 | 2023-2024 | Micra, Na, Cobalt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $76.21 | 2019-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $50.97 | 2021-2024 | Farxiga |
| Pfizer INC. | $42.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.23 | 2019-2022 | |
| Amarin Pharma, INC. | $37.68 | 2019-2020 | |
| Boston Scientific Corporation | $32.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.55 | 2019-2023 | |
| Philips North America LLC | $20.03 | 2022 | |
| Amgen INC. | $16.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Reese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.